First Trust Advisors LP Buys 42,211 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

First Trust Advisors LP lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 327,782 shares of the biopharmaceutical company’s stock after buying an additional 42,211 shares during the period. First Trust Advisors LP owned about 0.25% of Alnylam Pharmaceuticals worth $77,130,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ALNY. Larson Financial Group LLC increased its holdings in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $35,000. Versant Capital Management Inc boosted its position in Alnylam Pharmaceuticals by 77.6% during the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 83 shares during the period. Finally, IFP Advisors Inc grew its holdings in Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 47 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ALNY shares. Royal Bank of Canada raised their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research note on Friday, March 21st. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a report on Monday, March 31st. HC Wainwright reissued a “buy” rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. Finally, Stifel Nicolaus upped their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $315.58.

Alnylam Pharmaceuticals Trading Down 0.8 %

Shares of Alnylam Pharmaceuticals stock opened at $232.75 on Tuesday. The company has a market capitalization of $30.28 billion, a P/E ratio of -107.26 and a beta of 0.30. The stock has a fifty day simple moving average of $248.47 and a 200 day simple moving average of $256.64. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In related news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.